Callan JMB Inc(US:CJMB)2025-11-14 21:06Financial Performance - Revenues for Q3 2025 were $1.4 million, a slight increase from $1.4 million in Q3 2024, while revenues for the nine months ended September 30, 2025, were $4.6 million, down from $5.2 million in the same period last year [12]. - Gross profit for Q3 2025 was $0.5 million, compared to $0.5 million in Q3 2024, and for the nine months ended September 30, 2025, gross profit was $1.8 million, down from $2.1 million in the prior year [12]. - Loss from operations for Q3 2025 was ($1.9) million, compared to a loss of ($0.8) million in Q3 2024, and for the nine months ended September 30, 2025, the loss was ($4.5) million, up from ($1.0) million in the prior year [12]. - Net income for the nine months ended September 30, 2025, was a loss of $5,373,327, compared to a loss of $998,596 for the same period in 2024 [14]. - Net cash provided by (used in) operating activities was $(3,887,737) for the nine months ended September 30, 2025, compared to $1,263,526 in 2024 [14]. - Cash flows used in investing activities totaled $(616,896) for the nine months ended September 30, 2025, compared to $(46,167) in 2024 [14]. - Net cash provided by financing activities was $5,196,432 for the nine months ended September 30, 2025, compared to $(3,563,676) in 2024 [14]. - The company reported stock-based compensation of $1,154,842 for the nine months ended September 30, 2025 [14]. - The company experienced a decrease in accounts receivable of $(395,995) compared to an increase of $1,803,724 in 2024 [14]. - The company reported a decrease in inventory of $(64,883) for the nine months ended September 30, 2025, compared to an increase of $7,086 in 2024 [14]. - Proceeds from IPO and overallotment, net, amounted to $4,543,988 for the nine months ended September 30, 2025 [14]. - The company had a cash flow increase of $691,799 in cash and cash equivalents for the nine months ended September 30, 2025, compared to a decrease of $(2,346,317) in 2024 [14]. Operational Developments - The Company extended its emergency preparedness contract with the City of Chicago through June 2026, increasing total contract value to $9.1 million with an additional $1.5 million in funding [6]. - The Company established a subsidiary in India, Callan JMB Services (India) Private Limited, with plans for a temperature-controlled warehouse for pharmaceutical storage and distribution [6]. - The Company upgraded its Sentry Monitoring System to version 4.0, enhancing temperature monitoring capabilities for healthcare facilities and emergency management agencies [6]. - The Company entered a preliminary agreement to install oral drug delivery equipment at its cGMP facility in Texas, supporting future logistics operations for international pharmaceutical companies [6]. Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $2.8 million, an increase from $2.1 million at the end of 2024 [10]. - Total assets as of September 30, 2025, were $7.7 million, compared to $5.1 million at the end of 2024 [10]. - Cash and cash equivalents at the end of the period were $2,789,744, a decrease from $2,809,303 at the end of the same period in 2024 [14].